Skip to content

Clinical trials

Prostatic Neoplasms trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Country / region: United Kingdom Clear all

434 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20017
20024
20038
20045
20059
200615
200714
200813
200924
201014
201116
201216
201316
201427
201524
201623
201716
201814
201928
202017
202118
202218
202315
202420
202523
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed204
Recruiting69
Active, not recruiting57
Unknown status56
Terminated36
Not yet recruiting5
Withdrawn4
Suspended2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University College, London27
AstraZeneca26
Institute of Cancer Research, United Kingdom20
Royal Marsden NHS Foundation Trust19
Imperial College London13
Pfizer13
Janssen Research & Development, LLC12
Ferring Pharmaceuticals11
University College London Hospitals10
Bayer8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms434
Neoplasms41
Neoplasm Metastasis29
Breast Neoplasms26
Ovarian Neoplasms24
Urinary Bladder Neoplasms16
Carcinoma, Non-Small-Cell Lung15
Colorectal Neoplasms14
Endometrial Neoplasms12
Lung Neoplasms11

Trials

Showing 1 to 25 of 434. Each trial links to its page on Pharma Observatory.

334 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.